The Gen 1.0 biologics that provide immediacy and the Gen 1.5 biologics that provide immediacy and incremental durability are meaningful for patients and physicians Gen 1.0 Good efficacy, limited durability Gen 1.5 Immediacy Incremental durability Q4W Q8W Q12W Q16W Wet AMD DME DR RVO Wet AMD DME DR RVO Wet AMD DME RVO Wet AMD DME DR Dosing regimen per label for approved intravitreal biologics RVO Q8W dosing pending FDA approval Q20W Q24W $1.2B in 2024 $8.2B in 2024 $4.4B in 2024 $1.2B in 2024 This sustained commercial success is a testament to: • The power of the intravitreal biologic as the mainstay of therapy • The unmet need that remains for patients 17